CStone Receives Positive Recommendation from EMA for NSCLC Treatment
Saturday, 1 June 2024, 21:28
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
In an important step forward, the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cejemly (sugemalimab, anti-PD-L1) as a first-line treatment for non-small cell lung cancer (NSCLC). This recommendation follows a thorough review of the drug's efficacy and safety profiles, highlighting its potential in improving outcomes for NSCLC patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.